Circulating Tumor DNA(ctDNA) Testing to Detect Identical Gene Mutation Rates of KRAS, NRAS, PIK3CA and P53 Compared to Tissue-Based Testing and Reflects Treatment Efficacy in Patients with Colorectal Cancer.
Yanhong Deng,Weiwei Zhao,Liu Yang,Jiayu Ling,Linlin Mao,Huabin Hu,Yue Cai,Jianwei Zhang,Shihui Yu
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e23066
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e23066 Background: Molecular profiling for CRC commonly utilizes tissue, however, there are two major limitations. It is hard to overcome the complications of tumor heterogeneity and inconvenient to do multiple biopsies during the surveillance. While the alterations in KRAS have been shown to have a high degree of concordance between tissue and ctDNA testing, a detailed survey of other commonly mutated genes, and the influence of intervening treatment in CRC has not been conducted Methods: Tissue and blood samples underwent sequencing on a 50-gene hotspot AmpliSeq panel (IonTorrent) in a CLIA-compliant setting. The mutation rate and the concordance of gene mutations in tissue and in ctDNA were compared. Follow up blood draw was conducted in some patients Results: 161 patients with colorectal cancer underwent the test. 148 patients had tissue test, and 84 had ctDNA test, 63 had pairs of tissue and ctDNA. With the 50-gene hotspot tissue test, only 9.5% (14 in 148) of the patients did not have any mutation. The most common mutation gene was P53(72.3%, 107 in 148). The mutation rate of KRAS, NRAS, BRAF and PIK3CK in tissue was 45.1%, 4.6%, 5.1%, and 1.5% respectively. Whereas in blood, the mutation rate was 43.9%, 4.9%, 5.1% and 10.9% respectively. Both values are identical and in accord with the known prevalence of mutations observed in mCRC patient populations. In the paired 63 patients, the concordance for KRAS,NRAS, BRAF, PIK3CA and P53 was 96.6%, 100%, 96%, 97.9% and 90.9% respectively. In 25 patients who had more than twice ctDNA surveillance, the dynamic change of mutations in the blood was totally corresponding with the efficacy. 13 patients had no mutations detected after R0 resection, and 6 patients in 14 who received cetuximab treatment gain new mutations(RAS,EGFR,P53,SMARCB) before disease progression. 6 patients had dynamic gain and loss mutationS Conclusions: The common gene mutations rate in CRC detected in ctDNA is identical to that detected in tissue, is thus an appropriate surrogate testing in determining treatment options. And ctDNA reflects treatment efficacy, which warrants routine use in clinical practice